Does patient sex affect the treatment outcome of immune checkpoint inhibitors? A Danish, observational melanoma study

Skin Cancer

Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma

Eur J Cancer

Handel EE, McKeown J, Wei J, Kankaria RA, Burnette H, Johnson DB, Lawless A, Czapla J, Sullivan RJ, Albrecht LJ, Zimmer L, Mangana J, Dummer R, Kessels JI, Neyns B, Allayous C, Lebbe C, Boatwright C, Mehnert JM, Ottaviano M, Ascierto PA, Czarnecka AM, Rutkowski P, Lo SN, Long GV, Menzies AM, Carlino MS

doi: 10.1016/j.ejca.2024.115171

Skin Cancer

Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors

Eur J Cancer

Dimitriou F, Orloff MM, Koch Hein EC, Cheng PF, Hughes IF, Simeone E, Montazeri K, Grover P, Mehmi I, Gerard CL, Gaudy-Marqueste C, Grob JJ, Michielin O, Hamid O, Long GV, Sullivan R, Kapiteijn E, Johnson DB, Ascierto PA, Joshua AM, Carvajal RD, Butler MO, Hassel JC, Dummer R

doi: 10.1016/j.ejca.2024.115161

Skin Cancer

TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study

Int J Cancer

Virazels M, Lusque A, Brayer S, Genais M, Dufau C, Milhès J, Filleron T, Pagès C, Sibaud V, Mortier L, Dereure O, Ayyoub M, Fabre A, Andrieu-Abadie N, Pancaldi V, Colacios C, Meyer N, Ségui B, Montfort A

doi: 10.1002/ijc.35416

Genitourinary Cancer

The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Cancer Treat Rev

Zhang Y, Chen J, Liu H, Dai J, Zhao J, Zhu S, Zhang X, Liang J, Hu X, Zhao J, Liu Z, Shen P, Sun G, Zeng H

doi: 10.1016/j.ctrv.2024.102787

Breast Cancer

The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study

Eur J Cancer

Molinelli C, Bruzzone M, Blondeaux E, Ruelle T, Lanzavecchia C, De Laurentiis M, Russo S, Riccardi F, Sini V, Cognetti F, Arpino G, Fabi A, Pugliese P, Collovà E, Fontana A, Puglisi F, Bighin C, Lambertini M, Del Mastro L

doi: 10.1016/j.ejca.2024.115113

Genitourinary Cancer

Treatment options in first-line metastatic renal carcinoma: A meta-analysis of 2556 patients treated with immune checkpoint inhibitors-based combinations in randomised controlled trials

Cancer Treat Rev

Tucci M, Mandarà M, Giuliani J, Durante E, Buttigliero C, Turco F, Palesandro E, Campisi I, Singh N, Muraro M, Munoz F, Fiorica F

doi: 10.1016/j.ctrv.2024.102745

Genitourinary Cancer

Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study

Lancet

Choueiri TK, Albiges L, Barthélémy P, Iacovelli R, Emambux S, Molina-Cerrillo J, Garmezy B, Barata P, Basu A, Bourlon MT, Moon H, Ratta R, McKay RR, Chehrazi-Raffle A, Hammers H, Heng DYC, Braendle E, Beckermann KE, McGregor BA, Motzer RJ

doi: 10.1016/S0140-6736(24)01758-6

Skin Cancer

Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study

Eur J Cancer

Weichenthal M, Ellebaek E, Mangana J, Asher N, Gavrilova I, Kandolf L, Ugurel S, Hausschild A, Meier F, Leiter U, Livingstone E, Gebhardt C, Gutzmer R, Ruhlmann CH, Mahncke-Guldbrandt L, Haslund CA, Kopec S, Teterycz P, Bender M, Poudroux W, Muñoz-Couselo E, Berciano-Guerrero MA, Shalamanova G, DePalo DK, Brozić JM, Chiarion-Sileni V, Arance A, Ziogas D, Robert C, van de Velde AO, Gassama AA, Shapira R, BenBetzalel G, Grynberg S, Ramelyte E, Bertoldo F, DelPrete V, Gaudy-Marqueste C, Mohr P, Dummer R, Ascierto PA, Gogas H, Espinosa E, Lebbé C, Rutkowski P, Haanen J, Schadendorf D, Svane IM, EUMelaReg Consortium Members

doi: 10.1016/j.ejca.2025.115339

Further Publications

Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238

J Clin Oncol

Weber J, Del Vecchio M, Mandalá M, Gogas H, Arance AM, Dalle S, Cowey CL, Schenker M, Grob JJ, Chiarion-Sileni V, Márquez-Rodas I, Butler MO, Di Giacomo AM, de la Cruz-Merino L, Arenberger P, Atkinson V, Hill A, Fecher LA, Millward M, Khushalani NI, Queirolo P, Long GV, Lobo M, Askelson M, Ascierto PA, Larkin J

doi: 10.1200/JCO.23.01448

Related content

Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma

Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors

TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study

The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study

Treatment options in first-line metastatic renal carcinoma: A meta-analysis of 2556 patients treated with immune checkpoint inhibitors-based combinations in randomised controlled trials

Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study

Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study

Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238